Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of cancer for which treatment
with single agent paclitaxel would be an appropriate treatment option.

- At least 18 years of age.

- Patients can have received no more than two prior chemotherapy regimens for
metastatic disease. Patients may be currently receiving paclitaxel using one of the
schedules in the protocol, as long as the treating investigator has reasonable
expectation that the patient will continue to receive paclitaxel for 2 or more
additional cycles. The current regimen does not count towards the 2 regimens as long
as the patient is not progressing on therapy.

- Patients must have a life expectancy of more than 3 months.

- Patients must have a performance status of 0 to 2 according to the ECOG criteria.

- Patients must have normal organ and marrow function as defined below: leukocytes >=
4,000/microL, absolute neutrophil count >= 1,500/microL, platelets >= 100,000/microL,
HCT > 28%, total bilirubin < 2 x upper limit of normal, AST (SGOT)/ALT (SGPT) <= 2.5
X institutional upper limit of normal, creatinine <= 2.5 mg/dl transaminase < 2.5
times institution's upper normal limits

- Patients must have recovered from acute toxicity related to prior therapy, excluding
alopecia, including surgery or radiotherapy.

- Patients must be able to ingest oral medications.

- Female patients who are pregnant or lactating are ineligible. All females of
childbearing potential must have a negative serum pregnancy test within 72 hours of
treatment. Men and women of childbearing potential must agree to employ adequate
contraception to prevent pregnancy while on therapy and for four weeks after the
completion of treatment.

- Patients must have ability to understand and the willingness to sign a written
informed consent document.

Exclusion Criteria:

- Patients may not be receiving any other investigational agents or devices.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to perifosine (miltefosine or edelfosine).

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection and psychiatric illness/social situations that would limit compliance with
study requirements.

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study because of possible pharmacokinetic interactions with perifosine.

- Patients with a history of unstable or newly diagnosed angina pectoris, recent
myocardial infarction (within 6 months of enrollment) or New York Heart Assoc. class
II-IV congestive heart failure.

- Patients with a history of hypersensitivity reaction to products containing a
Chremophor EL.